← All trials
NCT06723197
Phase 4Interventional
Studies of FDA-approved drugs to delineate additional information including the drug's risks, benefits, and optimal use.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Dec 10, 2024
- Primary completion
- Oct 1, 2025
- Completion date
- Nov 30, 2025
- First posted
- Dec 9, 2024
- Last posted
- Dec 11, 2024
- Enrollment
- 330
- Arms / groups
- 3 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Shandong UniversityLead sponsor
- Shandong UniversitySponsor investigator
- Shandong UniversityCollaborator
- Qilu Hospital of Shandong UniversityCollaborator
- Feicheng Municipal People's HospitalCollaborator
- The People's Hospital of Jimo.QingdaoCollaborator
- Zaozhuang Municipal HospitalCollaborator
- Zibo Maternal and Child Health HospitalCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.